Looking beyond the spin of Big Pharma PR. But encouraging gossip. Come in and confide, you know you want to! “I’ll publish right or wrong. Fools are my theme, let satire be my song.” Email: jackfriday2011(at)hotmail.co.uk
Thursday, June 30, 2011
Wednesday, June 08, 2011
What word best describes J&J?
“Because of the diminished mental capacity of the patients being treated, this court finds the actions of the defendants, upon this (patient population), to be detestable,”
Friday, February 11, 2011
What were AstraZeneca's senior management telling Wall Street about Seroquel ten years ago?
Thursday, August 12, 2010
Thursday, March 11, 2010
J&J - Risperdal; Did J&J Plan to Break Rules?

Documents from a lawsuit by the state of Louisiana accusing J&J of off-label marketing shed fresh light on the company's long-standing desire to broaden the market for Risperdal beyond the ailments listed initially on the label—psychotic disorders linked to schizophrenia. J&J disclosed the documents from the suit, filed in the Opelousas district court in September 2004, after Bloomberg News asked the court to unseal them. The case is scheduled to go to trial in September.
As early as 1994, the filings show, the FDA ordered J&J's Janssen Pharmaceuticals unit, which developed Risperdal, to stop making false and misleading marketing claims about the drug's superiority to competing medicines. In 1999 the FDA warned J&J in a letter that its marketing materials for geriatric patients, including brochures, journal ads, and letters, overstated Risperdal's benefits while minimizing its risks. The letter said J&J misleadingly implied that Risperdal had been found effective for illnesses such as bipolar disorder and elderly psychosis. Months later J&J drew up a business plan that called for increasing Risperdal's market share in treatments for elderly dementia, aiming at $302 million in sales, the filings show.
"Egregious Examples"
Louisiana cited dozens of internal J&J files in its lawsuit claiming the company marketed Risperdal to the elderly and to children for unapproved, off-label uses. Professor Jerry Avorn of Harvard Medical School, who isn't involved in the case, says the papers add up to "one of the more egregious examples" of marketing drugs to vulnerable patients. Medical professionals know "that drug companies resort to unsavory practices to promote drugs," he says, but seeing the details of this campaign "is still pretty upsetting."More at BusinessWeek
Monday, November 16, 2009
J&J - Risperdal: mis-selling mistrial mid-trial
Superior Court Judge Darlene Pereksta today threw out Lynn Powell’s lawsuit at the end of a three-week trial in Trenton, New Jersey. The jury hadn’t yet heard closing arguments or started deliberations. Powell, 36, claimed she was fired in 2004 for protesting so-called off-label sales.
Powell didn’t testify at the trial, which began Oct. 27. Pereksta ruled that Powell failed to prove she engaged in whistle-blowing as defined in New Jersey’s Conscientious Employee Protection Act. Her failure to take the witness stand prevented jurors from weighing her claims that she tried to disclose her concerns about off-label marketing, the judge said.
“Had she testified as to her intent, the jury could have assessed her credibility,” Pereksta said. “Without any testimony as to her intent, the jury is left to speculate.”
J&J, the world’s largest health-products company, said Powell was fired by its Janssen Pharmaceutica unit for violating company policy against off-label marketing, a widespread practice in the industry. Risperdal was the fourth-biggest seller for New Brunswick, New Jersey-based J&J in 2008, with sales of $3.4 billion.
The Powell lawsuit was the first Risperdal sales case to go before a jury.
Monday, November 02, 2009
Thursday, October 29, 2009
Janssen - Risperdal: "probably" busted!
Matthew D. Thompson, testifying today in a trial over claims by a former co-worker, said that in 2002 he pushed doctors to consider prescribing Risperdal in combination with other drugs, so-called augmentation therapy, even though government regulators hadn’t approved this use. Janssen’s training didn’t include any specific prohibitions against promoting the drug that way, he said.
“I’m not saying the company tried to hide it, but we didn’t think about augmentation in the realm of on-label or off- label at that time,” Thompson said. He said he was “probably” aware that promotion of such sales was illegal.
Thompson was the third witness called in the case of Lynn Powell, 36, who claims she was fired in February 2004 for complaining within the company about pressure to promote Risperdal for children and bipolar disorder patients when it was approved only for adults with schizophrenia. Thompson was Powell’s supervisor when she was fired.
More



